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CMV is a common human herpesvirus that establishes life-
long infection in most people worldwide. Although infec-
tion is usually asymptomatic, CMV causes severe disease in 
the context of congenital infection and in transplant patients. 
This has prompted a long, and so far unsuccessful, search 
for a vaccine against CMV. In asymptomatic healthy carri-
ers, CMV elicits an extremely large, sustained humoral and 
cell-mediated immune response. Despite this, CMV has the 
unusual capacity to superinfect CMV-seropositive individu-
als. For these reasons, CMV is being ardently pursued as a 
vaccine vector, in particular for vaccination against HIV.
In a series of groundbreaking studies, Louis Pick-
er’s group vaccinated rhesus macaques with a rhesus CMV 
(RhCMV) vector encoding simian immunodeficiency virus 
(SIV) antigens (Hansen et al., 2011, 2013a,b, 2016). These 
macaques were then challenged repeatedly with SIV until 
they were unequivocally SIV infected. Of these vaccinated 
SIV-infected monkeys, 50% completely cleared the SIV in-
fection, a result not previously observed with any vaccine or 
in rare elite controllers (Hansen et al., 2011, 2013b). More-
over, the protection afforded by RhCMV-based vaccines was 
associated with very unusual CD8 T cell responses to both the 
vector and inserted SIV antigens (Hansen et al., 2013a, 2016). 
Normal immunodominance hierarchies were abolished; in-
stead, vaccine-elicited CD8 T cells recognized a broad array 
of peptides covering about two thirds of the antigenic pro-
teins. Many responses were promiscuous, recognizing peptide 
presented by allogeneic cells, and some supertopes were rec-
ognized by all animals regardless of MHC haplotype. Most 
strikingly, two thirds of CD8 T cells recognized peptide in the 
context of MHC II, and the remainder recognized peptide in 
the context of the nonclassical MHC Ib molecule MHC-E. 
This vaccine completely failed to elicit classically MHC 
I–restricted CD8 T cells in any macaque. The authors sug-
gested that these unconventional CD8 T cell responses were 
responsible for the RhCMV-SIV vaccine efficacy (Hansen 
et al., 2013a,b, 2016).
Such unconventional CD8 T cell responses are not a 
normal feature of the response to natural CMV infection in 
either monkeys or humans. In fact, these unconventional CD8 
T cells were only elicited by fibroblast-adapted RhCMV vec-
tors, i.e., viruses that had lost the pentameric glycoprotein 
complex that confers ability to infect most nonfibroblast cell 
types. Hansen et al. (2013a) propose that the altered tropism 
cytomegalovirus (cMV)-based vaccines have shown remarkable efficacy in the rhesus macaque model of acquired immune 
deficiency syndrome, enabling 50% of vaccinated monkeys to clear a subsequent virulent simian immunodeficiency virus chal-
lenge. the protective vaccine elicited unconventional cd8 t cell responses that were entirely restricted by MHc II or the non-
classical MHc I molecule, MHc-E. these unconventional responses were only elicited by a fibroblast-adapted rhesus cMV 
vector with limited tissue tropism; a repaired vector with normal tropism elicited conventional responses. testing whether 
these unusual protective cd8 t responses could be elicited in humans requires vaccinating human subjects with a fibro-
blast-adapted mutant of human cMV (HcMV). In this study, we describe the cd8 t cell responses of human subjects vaccinated 
with two fibroblast-adapted HcMV vaccines. Most responses were identified as conventional classically MHc I restricted, and 
we found no evidence for MHc II or HLA-E restriction. these results indicate that fibroblast adaptation alone is unlikely to 
explain the unconventional responses observed in macaques.
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is a probable mechanism for induction of these atypical CD8 
T cell responses. How loss of the pentameric complex so pro-
foundly impacts CD8 T cell responses is not yet understood. 
Nevertheless, if unconventional T cells are a key feature of the 
RhCMV vaccine efficacy, it is important to know whether 
similar responses are elicited by fibroblast-adapted, pentam-
eric complex–deficient CMV vaccines in humans.
Development of CMV vaccines is complicated by the 
limited host range of the virus. CMVs are found in most 
mammalian species and are highly species specific. Thus, the 
only way to test whether these unusual, protective CD8 T 
cell responses to fibroblast-adapted CMV occur in humans is 
to study the immune response in human subjects vaccinated 
with a fibroblast-adapted strain of human CMV (HCMV). 
We recently reported a phase I clinical trial to test the safety 
and immunogenicity of four live fibroblast-adapted HCMV 
vaccines that are chimeras of  Towne and Toledo strains (Adler 
et al., 2016). As with the RhCMV vaccines, these viruses lack 
the pentameric complex and have cellular tropism essen-
tially limited to fibroblasts, although the specific defect in the 
pentameric complex genes is different (Hansen et al., 2013a; 
Adler et al., 2016). Here, we report that the human CD8 
T cell response to fibroblast-adapted Towne/Toledo HCMV 
does not mirror the CD8 T cell response observed in rhesus 
macaques. On the contrary, humans vaccinated with Towne/
Toledo HCMV mounted CD8 T cell responses that were 
predominantly conventional in terms of immunodominance, 
breadth, core epitope length, and MHC restriction. These 
discrepant results may reflect differences between rhesus and 
human immune systems or differences, other than tropism, 
between RhCMV and HCMV vaccines.
rEsuLts And dIscussIon
towne/toledo HcMV chimeras are 
primarily fibroblast adapted
Sequence analysis showed that, in all four Towne/Toledo 
HCMV vaccines, the UL128-131 region derives from Toledo, 
which harbors a nonfunctional mutation in UL128 (Gen-
Bank accession nos. KX101021, KX101022, KX101023, and 
KX101024; Adler et al., 2016; Suárez et al., 2017). Therefore, 
these viruses should lack formation of the pentameric com-
plex, which is required for entry into epithelial, endothelial, 
and other nonfibroblast cell types and is believed to be im-
portant to elicit robust epithelial cell entry–specific neutral-
izing antibody responses (Cui et al., 2008). Consistent with 
the genetic predictions that all four vaccines lack pentameric 
complex expression, all subjects who seroconverted after vac-
cination had low epithelial-specific neutralizing antibody re-
sponses (Adler et al., 2016). Because tissue tropism is likely 
involved in the unconventional CD8 T cell responses observed 
in rhesus macaques, we tested the tropism of the Towne/ 
Toledo chimeras. We infected fibroblast, epithelial, endothe-
lial, and monocytic cell lines with wild-type HCMV strain 
TR; TRΔ4, which is derived from TR and lacks UL128-150; 
or each of the four Towne/Toledo HCMV vaccines (Fig. 1). 
All virus strains infected 100% of fibroblasts. In contrast, only 
wild-type TR infected epithelial and endothelial cells effi-
ciently. Wild-type TR infected monocytic cells more poorly 
than other cell types, so a multiplicity of infection (MOI) of 
100 was needed to infect ∼35% of differentiated THP-1 cells. 
At this higher MOI, TRΔ4 infected 6% and the four chime-
ras each infected <1% of THP-1 cells. Thus, Towne/Toledo 
HCMV vaccines demonstrate a cell tropism that is consistent 
with disruption of the pentameric complex and is similar to 
the RhCMV68-1 strain used as an SIV vector in macaques.
Vaccination with towne/toledo chimeras elicits narrowly 
focused cd8 t cell responses to IE-1
As previously reported, 8 out of 11 subjects who serocon-
verted after vaccination with low-dose (100 or 1,000 PFU) 
Towne/Toledo HCMV vaccines also mounted CD8 T cell 
responses. T cell responses were observed only in recipients of 
chimeras 2 and 4 (Table S1). All of these subjects responded 
to a peptide pool covering the immediate early 1 (IE-1) pro-
tein (Fig.  2  A). We previously reported that three subjects 
responded to one or more additional antigens (Adler et al., 
Figure 1. towne/toledo chimeras are fibroblast adapted. (A and B) 
Cell lines were infected with the indicated Towne/Toledo HCMV vaccines or 
control viruses at the following MOIs: fibroblasts (Fibro; NHDF), 3; epithelial 
(Epith; ARPE-19) and endothelial (Endoth; HUV EC) cells, 10; and monocytes 
(Mono; THP-1), 100. Delta 4 is a deletion mutant for UL128-150 and, thus, 
cannot form the pentameric complex. 24 h after infection, cells were stained 
for IE-1 and analyzed by immunofluorescence microscopy. (A) Immunoflu-
orescence photomicrographs of IE-1 expression in infected cells. Bar, 100 
µm. (B) Quantitation of proportion of infected cells. Data depict results 
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2016), but as IE-1 was the only antigen that elicited a mea-
surable CD8 T cell response from more than two subjects, 
we focused our detailed analysis on this antigen. Further-
more, assessment of the rhesus macaque CD8 T cell response 
to RhCMV antigens was restricted to IE-1 (Hansen et al., 
2013a). In that study, RhCMV-vaccinated macaques mounted 
CD8 T cell responses that showed broad epitope specificity, in 
contrast to the narrow focus on a few epitopes that is charac-
teristic of most CD8 T cell responses (Hansen et al., 2013a). 
We assessed the breadth of IE-1 peptide responses in all eight 
subjects who had measurable HCMV-specific CD8 T cell re-
sponses, and we found that each subject responded to only 
one to two peptides or peptide hot spots (two adjacent over-
lapping peptides; Fig. 2 B). This was similar to the breadth 
of responses in naturally HCMV-infected controls (Fig. 2 C). 
This contrasts with the extremely broad epitope specificity 
observed in RhCMV-vaccinated macaques, which responded 
to a mean of 36 IE-1 peptides (25% of all the overlapping 
peptides; Hansen et al., 2013a).
Most IE-1–specific cd8 t cells from towne/
toledo-vaccinated subjects recognize 
peptides presented by MHc I
The second unusual feature of the CD8 T cell responses to 
RhCMV fibroblast-adapted vectors is the complete lack of 
responses that are restricted by classical MHC I molecules; 
two thirds are MHC II restricted, and the remaining are 
MHC-E restricted (Hansen et al., 2013a, 2016). We used a 
combination of peptide truncations (Fig. 3, A–E), single HLA 
transfectant antigen-presenting cell lines (Fig.  3, F–K), and 
tetramer staining (Fig. 3 L) to assess the core epitope iden-
tity and HLA restriction of CD8 T cell responses in Towne/
Toledo vaccine recipients. The 10 response hotspots that were 
sufficiently robust to study are indicated with asterisks on the 
peptide maps (Fig. 2 B).
First, we noticed that several responses were identical 
to previously published HLA-B08–restricted responses to 
natural HCMV infection. Subjects 23 and 36 responded to 
IE-1 15mers 22 and 49–50 (Fig. 2 B). These peptides contain 
the 9mer sequences QIK VRV DMV (QV9) and ELK RKM 
MYM (EM9), which are previously described HLA-B08–re-
stricted HCMV epitopes (Kern, 1999; Wills et al., 2002; Elk-
ington et al., 2003). In both subjects, the QV9 responses were 
identified as HLA-B08 restricted using HLA-B08 transfec-
tants and tetramers (Fig. 3, F, G, and L), and in subject 23, the 
EM9 response was likewise HLA-B08 restricted (Fig.  3, F 
and L). It is important to note that we discovered that subject 
23 acquired a natural HCMV infection between 1 and 2 yr 
after vaccination (Adler et al., 2016). Leukapheresis occurred 
at 2 yr after vaccination, and that was the only time point 
at which there were sufficient PBMCs to perform the pep-
tide-spanning screen of IE-1 (Fig. 2). However, we assessed 
MHC class I restriction of the two IE-1 peptide responses 
from subject 23 on PBMC samples taken before the natural 
infection. Therefore, this assessment is measuring the response 
to the vaccination only (Fig. 3 F). In subject 36, only ∼10% 
of the EM9 response could be accounted for by HLA-B08 
restriction (Fig.  3 G). We conjecture that the remainder of 
the EM9 response may be HLA-B18 restricted in subject 36 
(Table S1); however, HLA-B18 single transfectants were not 
available for this study.
We definitively identified four additional classical 
MHC I–restricted responses using peptide truncations and 
peptide-pulsed single HLA transfectants. These were Cw3-, 
A3-, A2-, and A2-restricted responses from subjects 24, 28, 
30, and 34, respectively (Fig.  3, A, B, D, E, and H–K; and 
Table S1). In all cases, the proportion of CD8 T cells respond-
ing to peptide-pulsed single HLA transfectants was similar to 
the proportion responding when peptide was added directly 
to the PBMCs (Fig.  3, H–K). For subject 34, no individ-
ual IE-1 peptides elicited a response that rose consistently 
above background levels (Fig.  2  B), but we were able to 
grow a T cell line from this subject’s PBMCs. This line re-
sponded to two IE-1 peptides (Fig. 2 B), and one of these is 
HLA-A2 restricted (Fig. 3 K).
Of the three remaining responses (two in subject 28 and 
one in subject 34), there is reason to believe that two are also 
MHC I restricted. Single HLA transfectants were not avail-
able for all MHC I alleles for each of these subjects; however, 
peptide truncations revealed a pattern consistent with MHC 
I–restricted epitopes. First, responses were maintained until 
a critical single amino acid was lost from either the N or C 
terminus, at which point the response declined precipitously 
(Fig. 3, C and E). This pattern is typical of MHC I–restricted 
epitopes because the N and C termini of the peptide bind 
to the peptide-binding groove of the MHC I molecule and 
contribute important binding affinity, in contrast to the long 
MHC II–restricted peptides, which overhang the groove. 
Second, the core epitopes required for the responses were 
eight to nine amino acids long, which is typical for MHC I–
restricted responses. Subject 28 responded to a 9mer from the 
N terminus of the region spanning peptides 79–81 (Fig. 3 C 
and Table S1), and subject 34 responded to a 9mer shared 
between peptides 49 and 50 (Fig. 3 E and Table S1). Overall, 
we identified the classical MHC I allele that restricted 8 out 
of 12 detectable responses. Of the remaining four responses, 
three are consistent with MHC I restriction, as assessed 
by peptide truncations.
no evidence for MHc II or HLA-E restriction in cd8 t cell 
response to towne/toledo HcMV vaccines
Although we found most CD8 T cell responses to the HCMV 
vaccine were MHC Ia restricted, the restriction element for 
four responses from subjects 36, 28, and 34 remained uniden-
tified. Responses in subject 34 could not be studied further 
because the T cell line failed to survive. We tested whether the 
other three could be either MHC II or HLA-E restricted. To 
test for MHC II restriction, we tried to block responses using 
anti–MHC II antibodies or the class II–associated invariant 
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Figure 2. towne/toledo chimera vaccination elicits IE-1–specific cd8 t cell responses with narrow epitope breadth. (A) PBMCs were stimulated 
with solvent control (top) or an overlapping peptide pool covering the entire AD169 IE-1 protein (bottom), and antigen-specific responses were assessed by 
ICS. Plots are gated on live CD3+CD8+CD4− lymphocytes. Numbers on plots indicate the proportion of gated cells that are IFN-γ+TNF+. Subject 24 did not 
respond to this commercially available peptide pool (not depicted) but did respond to an overlapping peptide pool covering the entire IE-1 protein sequence 
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ies (Hansen et al., 2013a, 2016). We used CMV-specific CD4 
T cell responses from three naturally infected subjects as pos-
itive controls for MHC II–restricted responses. Preincubating 
PBMCs with CLIP had no impact on the CD4 T cell–positive 
control responses or on any of the vaccine subjects’ responses 
(not depicted). For antibody blockade, we used the same 
antibodies that had blocked the monkey responses and also 
an antibody recently reported to block an MHC II–restricted 
HIV-specific human CD8 T cell response (Ranasinghe et 
al., 2016). As reported in the Ranasinghe study, we found 
that MHC II–restricted responses in humans could only be 
blocked by a 20-fold higher concentration of antibody than 
was used in the Rhesus study (Hansen et al., 2013a). Using 
100 µg/ml of each of two anti–MHC II antibodies, we were 
able to block the majority of a CD4 T cell response in two 
of three HCMV-seropositive control subjects (Fig. 4 A). In 
the third subject, the same antibody combination blocked ap-
proximately one third of the CD4 T cell response. In contrast, 
anti–MHC II antibodies did not block any portion of the 
CD8 T cell responses to EK9 or peptides 79–81 in subject 
28 or to the EM9 peptide in subject 36 (Fig. 4, B and C). 
We observed even more inconsistent blockade of CD8 T cell 
responses in naturally infected CMV-seropositive controls 
with the anti–MHC I antibody W6/32; thus, in the absence 
of appropriate positive controls, we could not directly test 
whether the three orphan CD8 T cell responses in vaccinated 
subjects were MHC I restricted. We assessed potential HLA-E 
restriction of these responses by peptide pulsing HLA-E– 
expressing single transfectants (Fig.  4 F) but found no evi-
dence for HLA-E restriction (Fig. 4, D and E). These results 
cannot definitively exclude the possibility that these responses 
are restricted by either MHC II or HLA-E, particularly be-
cause antibody blockade is expected to be highly individual, 
depending on a match between the particular MHC alleles 
expressed and the specificity of the antibody. Nevertheless, 
these experiments provided no evidence to support uncon-
ventional restriction of these responses.
cd8 t cell responses to IE-1 peptides result from towne/
toledo HcMV vaccination and were not preexisting
The CD8 T cell responses to the Towne/Toledo chimeras 
were very small, consistent with the extremely low vaccine 
dose. We considered the possibility that these small responses 
could represent preexisting cross-reactive responses, rather 
than de novo responses to Towne/Toledo HCMV vaccination. 
We assessed kinetics of the defined IE-1 peptide responses, 
and in all cases, these responses did not exist before HCMV 
seroconversion (Fig. 5). This contrasts with a preexisting re-
sponse to a UL36 peptide in subject 36, which did not change 
after Towne/Toledo vaccination, and presumably represents a 
cross-reactive response (Fig. 5 F). Further, consistent with a 
specific vaccine-induced T cell response, subject 24 did not 
respond to the commercial Ad169 IE-1 peptide pool but did 
respond to a pool generated from the Toledo-derived IE-1 
sequence present in the chimera 4 vaccine administered to 
this subject (Fig. 2 A). As previously reported (Adler et al., 
2016), subject 23 was apparently exposed to wild-type CMV 
between 1 and 2 yr after vaccination. However, responses to 
both epitopes were clearly present after the vaccination and 
were then boosted by the infection. We conclude that these 
conventional IE-1–specific CD8 T cell responses were gen-
erated de novo in response to vaccination with the Towne/
Toledo chimera vaccines.
Overall, our results show that CD8 T cell responses to 
vaccination with Towne/Toledo fibroblast-adapted HCMV 
vaccines are very similar in breadth and MHC restriction 
to those elicited by natural HCMV infection. We positively 
identified the classical MHC I restriction element for the 
majority of responses, and none of the remaining responses 
appeared to be MHC II or HLA-E restricted. Irrespective 
of whether attenuated fibroblast-adapted HCMV vaccines 
may elicit rare MHC II– or HLA-E–restricted CD8 T cells, 
it is clear that the majority of CD8 T cell responses are con-
ventional, and several map to previously identified epitopes 
from natural CMV infection. This contrasts starkly with the 
rhesus vaccine, which elicited only MHC II– and MHC-E–
restricted T cell responses.
Why do attenuated fibroblast-adapted CMV vaccines 
elicit such different CD8 T cell responses in macaques versus 
humans? It is possible that the rhesus immune system has a 
greater propensity to mount these unusually restricted CD8 
T cell responses than does the human. Clearly, this is not the 
rule with all infections in macaques, as previously described 
CD8 T cell responses in macaques have been conventional. 
However, the rhesus MHC is much more polygenic than 
either the human or the mouse complex because of major 
duplication events in the MHC locus in old world monkeys 
since the most recent common ancestor with humans (Gibbs 
et al., 2007). Whereas individual humans and mice express 
up to six classical MHC I isoforms, an individual macaque 
peptide pool. Peptides are numbered from the N terminus and are indicated on the x axis. Responses were considered positive if the proportion of CD8 
T cells that was IFN-γ+TNF+ was >0.03% and >3 SD above background. Dotted lines represent cutoffs for positive responses for each subject. No individual 
peptide responses reached this threshold for subject 34, but upon growing a T cell line from subject 34 PBMCs, we identified two responses. The large 
response in subject 23 was subsequently determined to have arisen after natural HCMV infection between 1 and 2 yr after vaccination, but this response 
was present, albeit much lower, immediately after vaccine administration (Figs. 2 A and 5). Insufficient PBMCs were available to screen subjects 22 and 35 
for responses to individual 15mers. Asterisks represent responses studied in detail for core epitope identity and HLA restriction, summarized in Table S1. 
(C) PBMCs from naturally infected HCMV-seropositive controls were epitope screened as in panel B. Data show FACS plots from every subject analyzed and 
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Figure 3. Most cd8 t cells respond to epitopes presented by MHc I. (A–E) Peptide truncations were generated and used to stimulate PBMCs from 
the indicated subjects. Truncations were generated from either the single 15mer to which a subject responded or the 11mer-overlapping region when 
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can express as many as 22 classical MHC I isoforms, with 
Mamu-B being the most polygenic (Daza-Vamenta et al., 
2004; Otting et al., 2005). Likewise, an individual macaque 
haplotype can include many versions of Mamu-DR. The 
number of MHC isoforms expressed by individual macaques 
nears the theoretical maximum above which negative selec-
tion is predicted to either excessively delete the TCR reper-
toire or fail to negatively select autoreactive TCRs (Woelfing 
et al., 2009). Thus, it is possible that the unusual conditions 
for negative selection in the rhesus thymus could result in 
enhanced selection of CD8 T cells with ability to recognize 
peptide presented on MHC II or with nonclassical MHC I. 
Nonetheless, rare instances of MHC II–reactive CD8 T cells 
have been reported in humans, including in HIV-infected 
individuals (Ranasinghe et al., 2016), and HLA-E–restricted 
responses are common in response to Mycobacterium tuber-
culosis (Heinzel et al., 2002).
A nonmutually exclusive possibility is that, despite sim-
ilar viral tropism, genetic differences between RhCMV68-1 
and the Town/Toledo chimera vaccines contribute to the 
disparate CD8 T cell responses elicited in macaques versus 
humans. Unconventional CD8 T cell responses were only 
elicited by RhCMV vectors that lack the pentameric complex 
(Hansen et al., 2013a), and parsimony argues that the altered 
viral tropism resulting from loss of the pentameric complex 
causes unconventional CD8 T cell responses in macaques. 
However, another possibility raised by Hansen et al. (2013a) 
is that one or more of the proteins encoded in UL128-131 
has an additional function that affects generation of CD8 T 
cell responses. RhCMV68-1 lacks the rhesus orthologues 
of UL128 and UL130 (Malouli et al., 2012), whereas the 
Towne/Toledo chimeras used in our study have a defect only 
in UL128 (Suárez et al., 2017). Thus, despite similar cellular 
tropism (Fig. 1), genetic differences between RhCMV68-1 
and the Towne/Toledo HCMV vaccines could be responsible 
for the disparate CD8 T cell responses elicited in macaques 
versus humans. These differences could involve the pentam-
eric complex genes or other genes that differ between these 
viruses (GenBank accession nos. KX101021–KX101024). 
RhCMV and Towne/Toledo chimeras all encode intact im-
mune evasion genes known to impact the MHC I pathway 
(US2, US3, US6, and US11). Furthermore, the UL40 homo-
logue that impacts trafficking of MHC-E in CMV-infected 
cells is intact in RhCMV and in chimera 2 but disrupted in 
chimera 4 (GenBank accession nos. KX101021–KX101024; 
Suárez et al., 2017). However, with a genome of >200 kB 
containing possibly 200 open reading frames, there are many 
other genes whose functions may be important in shaping 
the CD8 T cell response in macaques and/or humans. Until 
we understand the mechanisms by which the RhCMV68-1 
vector elicits these unusual CD8 T cell responses in macaques, 
it is difficult to speculate which genes might be important.
Because of CMVs’ strict species specificity and marked 
coevolution with their hosts’ immune systems, translating in-
formation gained from CMV vaccine studies in nonhuman 
primates to a human vaccine is a daunting task. Overall, our 
results show that vaccination with fibroblast-adapted Towne/
Toledo HCMV did not elicit the unusual MHC II– and 
MHC-E–restricted responses predicted by RhCMV vac-
cine studies in macaques. If these unconventional responses 
are needed for protection against SIV/HIV, it is important to 
know how to elicit them in humans. If CMV cellular tropism 
is the primary determinant of unconventional responses in 
monkeys, eliciting them in humans could be difficult or im-
possible. However, if specific viral genes are the primary deter-
minant, the genetic sequences of the Towne/Toledo chimeras 
may provide useful information in designing HCMV vaccines.
MAtErIALs And MEtHods
Human subjects and study design
36 HCMV-seronegative male subjects received one of four 
live attenuated Towne/Toledo chimeric HCMV vaccines in a 
phase I dose escalation trial at Virginia Commonwealth Uni-
versity. Generation of vaccine strains, study design, study sub-
ject characteristics, and clinical assessment have been previously 
described (Heineman et al., 2006; Adler et al., 2016). This study 
was performed in accordance with the principles of the Helsinki 
Declaration. The Institutional Review Board of Virginia Com-
monwealth University approved the study, and informed writ-
ten consent was obtained from all subjects. Naturally infected 
HCMV-seropositive healthy control subjects were recruited at 
Oregon Health & Science University. The Institutional Review 
Board of Oregon Health & Science University approved the study, 
and informed written consent was obtained from all subjects.
show the amino acids that were removed in each truncation. The core epitope identified through truncations is shown in yellow below each graph. CD8 T 
cell responses were defined as in Fig. 2. (C) The 7mer peptide that overlaps peptides 79–81 to which subject 28 responded did not elicit a response, which 
indicates that this region contains two separate peptides. We identified the N-terminal peptide as EK9. Truncations of peptide 81 did not yield interpreta-
ble results. (F–K) Single HLA transfectants were pulsed with the indicated peptides for 1.5 h, washed extensively, and then used to stimulate PBMCs from 
subjects positive for that HLA allele. Peptide alone denotes that PBMCs were incubated directly with the indicated peptide rather than incubated with 
peptide-pulsed/washed single HLA transfectants. No HLA K562s denotes that PBMCs were cultured with peptide-pulsed, but untransfected, APC. Red boxes 
highlight HLA restriction of peptide responses. The dashed red box indicates HLA restriction that accounts for only a minority of the peptide response. 
Unless otherwise noted, the peptides used are those shown in Table S1. Transfectants were not available for every MHC I isoform of every subject, but all 
available transfectants were tested, and all transfectants strongly expressed HLA as assessed by flow cytometry (Fig. 4 and not depicted). Plots are gated on 
live CD3+CD8+CD4− cells. (F) Subject 23’s responses were assessed on PBMC samples obtained before the putative natural infection event. (L) PBMCs were 
stained with HLA-B08 tetramers folded with the indicated peptide. Plots are gated on live CD3+CD4−CD8+ lymphocytes. Data show responses from every 
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Viruses and infectivity assay
Generation of the vaccine strains has been previously described 
(Heineman et al., 2006). The HCMV clinical isolate TR-BAC– 
derived virus and the TRΔ4 virus lacking the UL-b′ region have 
been described previously (Ryckman et al., 2006). All virus stocks 
were made by infecting monolayers of normal human dermal fibro-
blasts (NHDFs) at an MOI of 0.1 PFU/cell. At 7–10 d after infection, 
infected cell supernatants were harvested, clarified by centrifuga-
tion at 5,000 g for 5 min, and stored at −80°C. The titers of virus 
stocks were determined by plaque assay on NHDFs. Propagation 
of NHDFs, human retinal pigmented epithelial cells (ARPE-19), 
and HUV ECs have been described previously (Vanarsdall et al., 
2008). THP-1 (monocytic) cells were from ATCC and were grown 
as recommended (TIB-202). To assess viral infectivity, monolay-
ers plated in 24-well dishes were incubated with virus stocks at 
MOIs of 3 for NHDFs, 10 for ARPE-19 cells and HUV ECs, and 
100 for THP-1 cells. Cells were incubated for 24 h at 37°C, fixed 
with 4% formaldehyde, permeabilized, and assayed by immunoflu-
orescent microscopy to detect the presence of the HCMV IE-1 
antigen as described previously (Vanarsdall et al., 2012). Virus 
entry was quantified by imaging at least three random fields and 
comparing the number of IE-1–positive cells to the total num-
ber of DAPI-stained cells.
Antibodies, peptides, tetramers, and cytokines
The following antibodies were used for flow cytometry analysis: 
CD3 (SK7; BD), CD4 (SK3; eBioscience), CD8 (RPA-T8; 
Figure 4. testing IE-1 peptide–specific 
cd8 t cells from towne/toledo 
HcMV-vaccinated subjects for MHc II and 
HLA-E restriction. (A–C) PBMCs were pre-
incubated with 100 µg/ml each of G46-6 and 
Tu39 MHC II–blocking antibodies or 200 µg/ml 
of isotype control antibody for 1 h before the 
indicated peptides were added. (A) Inhibition 
of CD4 responses by MHC II–blocking antibod-
ies in naturally infected HCMV-seropositive 
controls stimulated with overlapping peptide 
pools covering the indicated antigens. Plots 
are gated on live CD3+CD4+CD8− lymphocytes. 
(B and C) The peptides used were the 15mers 
or core epitopes shown in Table S1. Plots are 
gated on live CD3+CD4−CD8+ lymphocytes. 
(D and E) HLA-E single transfectants were 
pulsed with the peptides shown in Table S1, 
washed extensively, and then used to stimu-
late PBMCs from the indicated subjects. In the 
same experiment, RK9-pulsed HLA-A3 single 
transfectants were used as a positive control 
(subject 28). (F) MHC I expression on HLA-E 
and HLA-A3 single transfectants used in this 
experiment. Data show FACS plots from every 
subject analyzed and depict results of one ex-
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BD), CD69 (FN50; BioLegend), TNF (MAb11; eBioscience), 
IFN-γ (4S.B3; eBioscience), and MHC I (W6/32; Bio X 
Cell). The following functional grade antibodies were used 
to stimulate T cells in culture: CD28 (L293; BD), CD49d 
(L25; BD), and CD3 (SK7; eBioscience). The pan–anti–
MHC II–blocking antibody Tu39 and isotype control IgG2a 
κ were from BioLegend. The anti–HLA-DR–blocking 
antibody G46-6 was from BD. The 15mer-overlapping 
peptide pool covering Ad169 IE-1 and custom-made 
15mer-overlapping peptide pools covering the Towne and 
Toledo IE-1 sequences were from JPT Peptide Technologies. 
Individual peptides used for truncation studies and for puls-
ing HLA transfectants were synthesized by JPT or Genemed 
Synthesis Inc. HLA-B08 tetramers folded with the EM9 and 
QV9 peptides were from the National Institutes of Health 
tetramer core facility. Recombinant human IL-2, IL-4, and 
GM-CSF were from Immunex.
PBMc isolation
PBMCs were isolated via leukapheresis or from peripheral blood 
via Ficoll-Hypaque density gradient centrifugation. PBMCs 
were frozen in FBS/10%DMSO and stored and shipped in 
liquid nitrogen. PBMCs for all analyses except the kinetic data 
displayed in Fig. 5 were obtained at the following time points 
after vaccination: subject 23, days 56 (Figs. 2 A and 3) and 707 
(Fig. 2 B only); subject 24, days 256 and 319; subject 28, day 188; 
subject 30, day 125; subject 34, day 154; and subject 36, day 113.
Media
Cells were cultured in RPMI 1640 medium (Thermo 
Fisher Scientific) supplemented with 2  mM l-glutamine 
(Thermo Fisher Scientific), 100 U/ml penicillin (Invit-
rogen), and 100 µg/ml streptomycin (Invitrogen). RPMI 
medium was supplemented with 10% FBS (RPMI-10) for 
intracellular cytokine staining (ICS) and 10% or 2% human 
AB serum (RPMI-hu10 and RPMI-hu2, respectively) for 
T cell line generation.
Ics and flow cytometric analysis
Frozen PBMCs were rapidly thawed at 37°C, washed twice 
with warm RPMI-10 medium, plated at 0.5–1 × 105 cells 
per well in a 96-well plate, and rested overnight at 37°C and 
5% CO2 before peptide stimulation. Freshly isolated PBMCs 
were not rested before stimulation. PBMCs were stimulated 
for 8  h with 2 µg/ml anti-CD28/CD49d and 5 µg/ml of 
overlapping peptide pools, 20 µg/ml of single peptides, or 
peptide solvent to assess background. 3 µg/ml brefeldin A 
(eBioscience) was added at the time of stimulation or, when 
CD69 was to be assessed, after 2  h. PBMCs were stained 
with Live/Dead-Fixable Aqua (Thermo Fisher Scientific), 
followed by surface marker staining. Cells were fixed and per-
meabilized with a Cytofix/Cytoperm kit (BD) and stained 
for intracellular cytokines. Cells were run on an LSR II or 
LSRFortessa flow cytometer (BD) and analyzed in FlowJo 
(v. 9; Tree Star). CD8 T cells were gated as CD3+CD4−CD8+ 
Figure 5. cd8 t cell responses to IE-1 epitopes were 
generated de novo upon vaccination with towne/toledo 
HcMV and were not preexisting. (A–F) PBMCs from the 
indicated time points were stimulated with the indicated 
peptides and assessed as in Fig.  2. Unless otherwise noted, 
the peptides used were the 15mers or core epitopes shown 
in Table S1. Arrows indicate the date of seroconversion. 
(A) Subject 23 acquired a natural CMV infection between 
days 365 and 707, as assessed by epithelial cell–neutraliz-
ing titers that rose from undetectable (<1:10) at day 365 to 
1:6,600 at day 700. (C) Subject 28 was tested for responses 
to a peptide truncated from 15mer peptide 79 (aa 314–326: 
CYV LEE TSV MLAK) because removing the N′ cysteine and C′ 
arginine gave more robust responses. No PBMCs were avail-
able from this subject before seroconversion, but responses 
to all three IE-1 epitopes continued to rise until ∼200 d after 
vaccination, which strongly suggests that these were elicited 
de novo by Towne/Toledo vaccination. This contrasts with 
a UL36 peptide response in subject 36 that was preexisting 
(dashed line; F), which did not change upon vaccination. Data 
show responses from every subject analyzed and depict re-
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live lymphocytes. Positive CD8 T cell responses were defined 
as the IFNγ+TNF+ proportion that was >0.03% and more 
than three standard deviations above background.
In some experiments, PBMCs were stimulated with 
peptide-pulsed single HLA-transfected K562 cells. K562 
cells were cultured in RPMI-10 medium overnight at 27°C 
to increase MHC expression and then pulsed with 10 µg/
ml peptide for 1.5 h at 37 or 27°C and washed three times 
with PBS and once with RPMI-10 medium. Then, PBMCs 
were stimulated with anti-CD28/CD49d and peptide-pulsed 
K562 at a 1:10 ratio and assessed for cytokine production by 
ICS, as described in the previous paragraph.
For MHC II–blocking experiments, 100 µg/ml each 
of Tu39 and G46-6 anti–HLA-DR or 200 µg/ml of iso-
type control (IgG2a κ) were preincubated with PBMCs 
for 1  h before addition of peptide. For tetramer staining, 
PBMCs were used immediately upon thawing. Cells were 
costained with allophycocyanin (APC) and FITC-labeled 
HLA-B08:01 tetramers concurrently with all other surface 
markers. CD8 T cells were gated as CD3+CD4−CD8+ live 
lymphocytes and were considered tetramer binding if posi-
tive for either APC or FITC.
HLA transfectants
Stably transduced HLA-E–expressing K562 cells were pro-
vided by Jonah Sacha (Oregon Health & Science Univer-
sity Vaccine and Gene Therapy Institute, Beaverton, OR; 
Hansen et al., 2016). HLA-A1:01, A2:01, A11:01, B8:01, 
and B44:03 were transduced into K562 cells. HLA-A3:01, 
A24:02, A26:01, A33:03, B14:02, B44:02, Cw01:02, and 
Cw03:03 were transfected into K562 cells and grown in se-
lection media containing 250 µg/ml G418 (Sigma-Aldrich). 
MHC expression was assessed regularly by flow cytometry 
with W6/32 pan–anti–MHC I antibody.
Generation of t cell line
An IE-1–specific CD8 T cell line was generated from sub-
ject 34. PBMCs were magnetically enriched for CD8 T cells 
by EasySep negative selection (STE MCE LL Technologies). 
T cells were cultured with 5 ng/ml IL-2 in RPMI-h10 
medium and stimulated at a 10:1 ratio with autologous 
monocyte-derived DCs pulsed overnight with 2.5 µg/ml 
of the HCMV IE-1–overlapping peptide pool. On day 8, T 
cells were labeled with CFSE (Invitrogen) and restimulated 
at a 1:10 ratio with 2.5 µg/ml autologous peptide-pulsed 
monocyte-derived macrophages plus 5 ng/ml IL-2. 7 d later, 
CFSE-low cells were FACS sorted and rapidly expanded 
after overnight rest in 0.5 ng/ml IL-2. T cells were ex-
panded with 30 ng/ml soluble anti-CD3 and a 10–20-fold 
excess of irradiated feeder cells. Feeder cells consisted of a 
5:1 ratio of autologous PBMCs (30 Gy) to allogeneic lym-
phoblastoid cell lines (60 Gy). On day 5, cells were washed 
and given fresh RPMI-h10 medium with 2 ng/ml IL-2. 
IL-2 was replenished every 2–3 d thereafter. The T cell line 
was assessed functionally beginning on 11 d after CFSE-
low sort, and some cells were frozen for subsequent anal-
ysis. Upon thawing, the T cell line was rapidly expanded 
before functional analysis.
Monocyte-derived dcs and macrophages  
for generation of t cell line
The protocol for differentiating autologous monocyte-de-
rived DCs was adapted from Romani et al. (1994). In brief, 
PBMCs were incubated in RPMI-h2 with 60 µg/ml DNase 
for 1 h. Media was aspirated, and attached monocytes were 
washed two times with PBS. Monocytes were differenti-
ated to DCs in RPMI-hu10 supplemented with 10 ng/ml 
GM-CSF and 10 ng/ml IL-4 for 8 d. Autologous macro-
phages were differentiated from magnetically isolated CD14+ 
PBMCs (autoMacs Pro Separator; Miltenyi Biotec) by plat-
ing at 106/ml on tissue culture–treated plates and culturing 
5 d in RPMI-h10 medium.
HLA typing
HLA typing was performed on DNA isolated 
from PBMCs by ProImmune.
online supplemental material
Table S1 shows a summary of vaccine chimeras and doses ad-
ministered, epitopes and HLA restriction of T cell responses, 
and HLA typing for each subject.
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